EpCAM(Epithelial Cell Adhesion Molecule)Is aIA type of transmembrane glycoprotein that is uniformly and highly expressed on the cell membranes of various human epithelial-derived tumors, including esophageal cancer, colorectal cancer, pancreatic cancer, ovarian cancer, lung cancer, gastric cancer, and breast cancer.【1】, while its expression in normal tissues is relatively low.【2】. In a study,129Example: Normal gastric mucosa was not observed.EpCAMExpression, but in77%Observed in Gastric CancerEpCAMExpression and56%For medium to high expression【3】. Due toEpCAMAfter the malignant transformation of the tumor, it changes from the basal lateral side to a uniform expression on the cell membrane surface.And it shows high expression in primary lesions, metastatic lesions, and circulating tumor cells, which makesEpCAMHas becomeCAR-TA Potential Target for Cell Therapy，And demonstrated potential application value in the treatment of various epithelial-derived tumors.。Due to the complex microenvironment of solid tumors and high target heterogeneity,CAR-TProgress in therapy for solid tumors has been limited over the long term.IMC001With its unique target selection and innovative technology design,Demonstrated potent anti-tumor activity in preclinical studies. This therapy in patient-derived organoids（PDO）In models and mouse models, forEpCAMPositive tumor cells exhibit efficient killing ability, fully demonstrating their efficacy in preclinical studies.。Recently,ImmunofocoInMolecular TherapyThe magazine published an article titledPreclinical development and a phase I trial of IMC001, an EpCAM-targeted CAR-T cell therapy, in patients with advanced gastric cancerArticle。Validated through comprehensive preclinical models and clinical trials in patients with advanced gastric cancer.IMC001The anti-tumor activity and good safety. Especially at the medium dose, the confirmed objective response rate（ORR）Up to40%, and no dose-limiting toxicity has occurred, fully demonstrating the targetingEpCAM CAR-TThe Potential of Therapy in the Field of Advanced Gastric Cancer Treatment。
In the first-in-human clinical trial,IMC001Similarly achieved good results. From2021Year8Moon Arrival2023Year5Month, thisIPhase, Open-label, Dose-escalation and Dose-expansion Study Enrolled a Total of12Patients with advanced gastric cancer who have received multiple lines of treatment. The results showed that, in the evaluable10Among the patients,IMC001Achieved30%Objective Response Rate（ORR）And70%Disease Control Rate（DCR）`, Median Progression-Free Survival`（mPFS）Achieve4.5months, median overall survival（mOS）For8.4Months. Among them,A Case of Advanced Gastric Cancer in the Final Line Showed Significant Tumor Reduction After Treatment, During Infusion27Successfully underwent conversion surgery and completed radical resection weeks later. As of2025Year4Month28The patient survived after infusion in Japan.34.7Months。This case not only demonstratesIMC001Shows great potential in extending survival for advanced gastric cancer and offers new insights for future treatment strategies.。IMC001The early clinical research and clinical trial data for patients with advanced gastric cancer not only validatedEpCAMAsCAR-TThe feasibility of the therapeutic target has shown us its broad prospects in the treatment of gastric cancer and other solid tumors. We look forward to collaborating with peers both in China and internationally, accelerating the clinical translation of this innovative therapy, and benefiting more patients as soon as possible.Original link:https://linkinghub.elsevier.com/retrieve/pii/S1525001625006446
Plate Maker: Eleven
Academic Cooperation Organization
(*The ranking is不分先后)
Reprint Notice
[Non-Original Article] The copyright of this article belongs to the author. Personal sharing and forwarding are allowed, but reproduction without the author's permission is prohibited. The author reserves all legal rights, and violators will be held accountable.
